MedPath

Excimer Light(308) Therapy for Resistant Alopecia Areata

Not yet recruiting
Conditions
Alopecia Areata
Registration Number
NCT06149936
Lead Sponsor
Assiut University
Brief Summary

This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .

Detailed Description

Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • ● Having multiple patches of AA.

    • Duration of alopecia >1 year
    • No topical or systemic treatment for the last 4 months
    • Agreement to regular visits for treatment and follow-up.
Exclusion Criteria
  • ● A single form of AA.

    • Alopecia for <1 year.
    • Being on other modalities of treatment.
    • Treatment within the last 4 months.
    • Photosensitive disorders.
    • Pregnancy or breastfeeding.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
alopecia areata with ecimer light3 months

evulate patients monthly during treatment with excimer light and minoxidil gel for three months With 20 patients who should completely recovered from alopecia areata.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath